Compare PulteGroup, Inc. (PHM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Tango Therapeutics Inc. — how do they compare? PulteGroup, Inc. trades at $110.09 (market cap $20.83B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: PulteGroup, Inc. is far larger — about 5.6× Tango Therapeutics Inc.'s market cap, and PulteGroup, Inc. pays a 0.95% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Tango Therapeutics Inc. for 0 Days on average.
| PHM | TNGX | |
|---|---|---|
Market Cap | $20.83B | $3.74B |
Volume | 2,206,640 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $32.90 |
52-Week Low | $109.35 | $7.50 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $21.24B | $2.76B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $111.58, down 0.4% with a bearish technical signal. The stock shows mixed earnings performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing. Revenue declined to $17.31B in 2025 with net income margin at 11.62%. Recent news highlights pressure from rising mortgage rates affecting homebuilder stocks, with PHM falling more than broader markets in September 2026.
The outlook remains cautious amid housing market headwinds from rising yields. Analyst consensus is divided with 45% buy ratings but a $139.64 price target suggests 25% upside. Key risks include mortgage rate sensitivity and competitive pressures, while valuation metrics appear reasonable with P/E of 11.4.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
